Teva said the FDA approved its generic version of Procter & Gamble Actonel (risedronate sodium tablets) in 5 mg, 30 mg and 35 mg doses to treat and prevent postmenopausal and glucocorticoid-induced osteoporosis, and to treat Paget’s disease. Actonel had US sales of about $1 billion, for the 12 months ended June 30, based on IMS sales data.